GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?

Ellie-May Beaman, David R. F. Carter and Susan A. Brooks*

Department of Biological & Medical Sciences
Oxford Brookes University, Headington, Oxford, OX3 0BP, UK.

*Corresponding author: Department of Biological & Medical Sciences, Oxford Brookes University, Headington, Oxford, OX3 0BP, UK. Email sbrooks@brookes.ac.uk

Running head: GALNTs regulate epithelial-mesenchymal transition

Keywords: Epithelial-mesenchymal transition (EMT) / GalNAc O-glycosylation / metastasis / Tn antigen / UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases (GALNTs)

Statement of conflict of interest: The authors are Founders of, and hold shares in, MetaGuideX Ltd., a spinout company based at Oxford Brookes University with an interest in glycans as cancer biomarkers.
Abstract

In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminytransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes. They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation. This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis. Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers. These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen. Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models. We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis. Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
The extensive family of UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminytransferases

In humans, there are 20 isoenzymes in the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminytransferases family, also known as ppGalNAc-Ts, GalNAc-Ts or GALNTs. They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation. This initial structure is then usually extended by the further sequential action of glycosytransferases to build more complex linear or branched structures (see Brooks et al., 2002; Brockhausen and Stanley, 2017 for detail). The GALNTs are by far the largest known glycosyltransferase enzyme family, and stand in contrast to the situation in other types of protein glycosylation where just one or two enzymes are responsible for the addition of the glycan to the amino acid of the polypeptide (Clausen and Bennett, 1996; Bennett et al., 2012). Members of the family are designated GALNT1 to GALNT20 following the order in which they were first described. Table I gives a summary of the accession numbers and gene locations of the GALNTs, plus a note of any alternative terms by which they were reported before the CAZy nomenclature (http://afmb.cnrs-mrs.fr/fr/CAZY/) was agreed. It is believed that all GALNTs, except for GALNT4, arose through evolution from an ancestral GALNT gene, with nine members of the GALNT family being present in Caenorhabditis elegans, fourteen in Drosophila species, twenty-one in fish, and nineteen in mice. They are present in all metazoans, but not in yeasts or plants (Hashimoto et al., 2009). Figure 1 illustrates the proposed phylogenetic tree for the GALNT gene family based upon subfamily clusters (reviewed by Bennett et al., 2012).

All GALNTs except GALNT20 share a type II membrane structure, illustrated in Figure 2, composed of a short N-terminal cytoplasmic tail (Smith and Lupashin, 2008), a hydrophobic membrane-spanning domain, a stem region (90 amino acids, for GALNT1, -T13, -T16; 170 amino acids for GALNT3, -T8, -T15; and 470 amino acids for GALNT5) (Bennett et al., 2012), a luminal catalytic domain (about 230 amino acids long) (Paulson and Colley, 1989) and, unique to the GALNTs, a C-terminal ricin-like lectin domain (about 120 amino acids long) which has a binding specificity for α-GalNAc monosaccharides.
GALNT10 has an additional binding pocket in the catalytic domain (Kubota et al., 2006). GALNT20 does not have the lectin domain, but does share the other structural components of the family (Bennett et al., 2012).

The reasons why so many GALNTs are required for initiation of mucin type O-glycosylation is not completely understood. However, it does not appear to represent redundancy or a duplication of function (Hassan et al., 2000). GALNTs show different, albeit partly overlapping, substrate specificities, kinetic properties and catalytic activities, have preferences for the proline in the glycosylation site being in the -1 or-3 position, exhibit differential temporal, spatial and tissue-specific expression (described below), and some GALNTs will only glycosylate proteins already glycosylated by a GalNAc (reviewed by Bennett et al., 2012; Wandall et al., 2021). This allows for fine differential regulation of O-glycosylation distribution and density. GALNTs may be categorised based on their in vitro substrate preferences as: “early”, which act on naked peptides/proteins, such as GALNT1 and -T2; “mid”, which have a preference for peptides neighbouring prior GalNAc glycosylated peptides, such as GALNT4; and “late”, which strictly act on areas of high GalNAc glycosylation, such as GALNT7 and -T10 (Ten Hagen et al., 1999; Hassan et al., 2000; Pratt et al., 2004; Bennett et al., 2012, and reviewed by Ten Hagen et al., 2003; de las Rivas et al., 2019).

Li et al. (2012) reported a sub-family, which they designated the Y subfamily, and which are only expressed in vertebrates. It comprises GALNT8, -T9, -T17 and -T18, and all share a common mutation in the catalytic domain, such that they have lost their transferase activity. The remaining sixteen GALNTs are termed the W subfamily. GALNT18 has been demonstrated to modulate the catalytic activity of W family GALNTs. On the basis of this, Li et al. (2012) postulate that Y subfamily GALNTs may act as molecular chaperones to W subfamily GALNTs in a similar manner to the way in which Cosmc acts as a chaperone to core 1 synthase during extension of O-linked glycans, thus facilitating a subtle level of regulation of GalNAc O-glycosylation.
There are some inconsistencies in the literature regarding the overall tissue expression patterns of the GALNTs. Toba et al. (2000) reported that GALNT1, -T2, -T4 and -T8 are ubiquitously expressed, whilst GALNT3, -T5, -T6, -T7 and -T9 are tissue-specific, with GALNT9 expression being limited to brain. Zhang et al. (2003) reported that GALNT1, -T2, -T4, -T7, -T8, and T12 are expressed ubiquitously, whilst GALNT3, -T6, -T9 and -T11 are restrictively expressed. Peng et al. (2010) reported that GALNT1, -T2, -T4, -T7 and -T8 are ubiquitously expressed, whilst GALNT3, -T5, -T6, -T9, -T10, -T11, -T12, -T13, -T14, -T15, -T16 and -T20 are more selectively expressed; they were unable to detect expression of GALNT16, -T18 and -T19. Bennett et al. (2012) reported that GALNT1, -T2 and -T7 show ubiquitous expression, while GALNT3, -T4, -T6, -T11, -T12, -T14, -T16 and -T18 show a more limited distribution, and GALNT5, -T8, -T9, -T10, -T13, -T15, -T17, -T19 and -T20 are highly restricted in expression. They also commented that the GALNT20 reported by Peng et al. (2010) was mis-identified and was actually GALNT17. However, all published reports agree that GALNT1 and -T2 are distributed ubiquitously in human tissues (Homa et al., 1993; White et al., 1995; Toba et al., 2000; Zhang et al., 2003; Peng et al., 2010; Bennett et al., 2012). The literature also indicates that some GALNTs are normally widely distributed across human tissues, whilst others show more limited and discrete patterns of expression, summarised in Table II.

**Relocation of the GALNTs in cancer and exposure of cancer-associated Tn antigen**

Since the GALNTs are responsible for initiation of mucin-type GalNAc O-linked glycosylation, alterations in their distribution, expression or activity would be predicted to result in alterations in this type of glycosylation including, but not exclusively, the synthesis of truncated O-linked glycans such as Tn antigen. The GALNTs are normally located throughout the Golgi apparatus (Röttger et al., 1998). However, it has been reported that in cancers GALNTs are often relocated to the endoplasmic reticulum, termed the GALA (GalNAc-T activation) pathway (Gill et al., 2011; Chia et al., 2014; 2016; 2019; Gomes et al., 2017). This results in the synthesis of proteins glycosylated with unelaborated Tn
antigen. Tn antigen is almost always further extended in normal adult tissues and therefore ordinarily present at very low levels. However, unelaborated Tn antigen is a recognised feature of around 50-90% of all cancers, where its exposure has often been reported to be associated with metastatic potential and poor patient prognosis (for example, Springer, 1984; Ju et al., 2008; Julien et al., 2012). Recently, Rømer et al. (2021) reported Tn immunolabelling of a more than 700 normal and cancer tissue samples, and found high levels in cancers arising from breast, colorectum and pancreas, but negligible or undetectable immunoreactivity in normal tissues or cancers derived from the central nervous system or mesenchymal tissue.

Exposure of Tn antigen could also be attributed to factors other than GALNT relocation to the endoplasmic reticulum. There is evidence, for example, that the pH and redox potential within the Golgi apparatus influences the location of glycosyltransferases, and therefore patterns of O-linked glycosylation (Axelsson et al., 2001; Hassinen et al., 2019). There has also been a long standing hypothesis that Tn antigen exposure in cancer could result from a failure of normal chain extension (Ju et al., 2011), arising from lack of expression of the core 1 synthase, β1,3 galactosyltransferase (C1GALT1), or loss of its molecular chaperone, Cosmc (Ju and Cummings, 2002; Ju et al., 2008). There is some evidence for this; for example, Thomas et al. (2019) showed that knockdown of Cosmc resulted in accumulation of Tn antigen and increased epithelial mesenchymal transition (EMT) a feature of metastatic cancer cells, described later, in pancreatic cancer cells. Some studies have provided evidence that epigenetic modification through hypermethylation of the Cosmc promoter results in silencing of C1GALT1 and therefore synthesis of unelaborated Tn antigen (Mi et al., 2012; Jiang et al., 2018; Xu et al., 2020a). However, core 1 is frequently observed in cancers that also feature Tn antigen (Baldus et al., 2000; Yu, 2007; Kölbl et al., 2016; Sindrewicz et al., 2016) which, if the presence of Tn antigen were due to the absence of Cosmc or core 1 synthase, would be predicted not to occur. Alternatively, decreased expression of β1,3GlcNAc-T (C3GnT), the transferase responsible for addition of a GlcNAc monosaccharide to Tn antigen to form core 3, GlcNAcβ1,3GalNAc-O-Ser/Thr, can also lead to enhanced exposure of Tn and sialyl Tn (An et al.,
Finally, both UDP-Gal and the UDP-Gal transporter are necessary for chain extension, and their absence can also result in increased levels of Tn antigen (Deutscher et al., 1986; Kingsley et al., 1986; Stanley et al., 1991). There are therefore several mechanisms by which unelaborated Tn antigen may feature in cancers, but evidence suggests that GALNT relocation to the endoplasmic reticulum, the GALA pathway, is prominent among them.

**Alterations in levels of GALNTs in cancer**

That exposure of Tn antigen is a feature of many cancers and is associated with poor patient prognosis is well established, and relocation of GALNTs within the secretory pathway appears to be the most important mechanism underlying its appearance. Altered levels of GALNT expression or distribution, determined by molecular approaches and by immunohistochemistry, respectively, have also been extensively reported in a broad range of cancers. These include colorectal (Kohsaki et al., 2000; Shibao et al., 2002; Guo et al., 2004; Guda et al., 2009; Abulí et al., 2011; Clarke et al., 2012; Lavrsen et al., 2018; Ubillos et al., 2018; Tang et al., 2021), gastric (Onitsuka et al., 2003; Gomes et al., 2009; Gao et al., 2013; He et al., 2014; Xu et al., 2020b; Liu et al., 2016), renal (Kitada et al., 2013), breast (Berois et al., 2006a; Freire et al., 2006; Patani et al., 2008; Wu et al., 2010; 2021a; 2021b; Park et al., 2010; Liu et al., 2020; Huang et al., 2022), pancreatic (Li et al., 2011; Taniuchi et al., 2011; Tarhan et al., 2016; Caffrey et al., 2019), gallbladder (Miyahara et al., 2004), prostate (Landers et al., 2005), oesophageal (Ishikawa et al., 2005), lung adenocarcinoma (Gu et al., 2004; Song et al., 2020; Wang et al., 2021) and non small cell lung cancer (Dosaka-Akita et al., 2002), cervical (Peng et al., 2012; Cao et al., 2020), bladder (Ding et al., 2012), liver (Wu et al., 2011; Huang et al., 2015), oral (Lin et al., 2014; Harada et al., 2016), ovarian (Wang et al., 2014; Yang et al., 2016; Lin et al., 2017; Li et al., 2021), glioma (Sun et al., 2019), chronic lymphocytic leukaemia (Libisch et al., 2014) and neuroblastoma (Berois et al., 2006b; 2013; Ho et al., 2014). A summary of these studies is given in Table III.
Clearly, such changed expression of GALNTs would be predicted to result in both altered levels of site specific O-linked glycosylation, and, potentially, changes in the glycan structures formed, including exposure of truncated O-glycans such as Tn antigen. Several of the studies cited (indicated in Table III) attempted to correlate increased or decreased levels of specific GALNTs with altered GalNAc O-glycosylation in cancer cells. Most commonly, this was approached by using lectin pulldown from cell lysates using the lectin *Vicia villosa* agglutinin (VVA) which has a reported specificity for Tn antigen, VVA labelling of specific target proteins on western blots, and/or VVA lectin cytochemistry. However, results of such analyses should be interpreted with a degree of caution in terms of them indicating synthesis of proteins glycosylated with Tn antigen. Firstly, whilst VVA has been extensively employed to identify Tn antigen, it is also reported to recognise other glycan structures (Tollefsen and Kornfeld, 1983; Iskratsch et al., 2009). Some studies, for example, that of Libisch et al. (2014) on GALNT11 in chronic lymphocytic leukaemia, addressed this by also employing monoclonal antibodies against Tn antigen. Moreover, many of the studies cited interpreted VVA binding to either permeabilised cells or to proteins from cell lysates as evidence of increased GalNAc O-glycosylation, but this may not mean that the mature target proteins carry Tn antigen. Detarya et al. (2020), in their study of GALNT5 in cholangiocarcinoma, illustrated that whilst VVA labelling could be localised in permeabilised cells to the peri-nuclear space in cells over expressing GALNT5 – presumably representing enhanced initiation of GalNAc O-glycosylation in the Golgi apparatus or endoplasmic reticulum - no cell surface VVA labelling of mature glycoproteins was detectable. This suggests that whilst these may be O-glycosylated by the GALNT, they did not feature unelaborated Tn antigen.

As indicated in Table III, many studies have reported differences in levels of GALNTs between normal in comparison with cancer tissues. In many cases, differences were shown to have prognostic significance in clinical studies, or to be associated with altered cell behaviour *in vitro* – commonly, proliferation, migration in wound healing or transwell assays, or invasion through matrigel – or altered tumorigenicity in animal models. For example, increased expression of GALNT1 has been
reported to predict poorer survival in liver cancer patients (Huang et al., 2015). Reports suggest that high GALNT2 levels predict poor prognosis in some cancer types, such as lung adenocarcinoma (Wang et al., 2021), and glioma (Sun et al., 2019). However, they are associated with good prognosis in other cancers, such as neuroblastoma, where immunopositivity has been reported to be associated with early stage (Ho et al., 2014), reduced levels to be associated with advanced disease and shorter recurrence free survival in gastric cancer (Liu et al., 2016), and with vascular invasion and recurrence in hepatocellular carcinoma (Wu et al., 2011). Similarly, increased GALNT3 appears to be associated with good prognosis in some cancer types, and poor prognosis in others. Elevated levels of GALNT3 have been reported to predict improved survival in colorectal (Shibao et al., 2002) and gastric cancers (Onitsuka et al., 2003), and low levels to predict poor prognosis in lung adenocarcinomas and non small cell lung cancers (Gu et al., 2004; Dosaka-Akita et al., 2002). Conversely, GALNT3 positive oesophageal cancers have been reported to be more likely to have metastasised (Ishikawa et al., 2005) and GALNT3 positive renal carcinomas to be larger, feature vascular invasion and have poorer survival (Kitada et al., 2013). GALNT3 positive oral squamous carcinomas have been reported to be poorly differentiated, feature vascular and lymphatic invasion and be more likely to recur (Harada et al., 2016), and high GALNT3 levels to predict shorter progression free survival in epithelial ovarian cancers (Wang et al., 2014). Wu et al. (2021a;b) report increased GALNT4 to be associated with enhanced recurrence free survival in breast cancer. Reduced levels of GALNT5 have been reported to predict poor prognosis in gastric cancer (He et al., 2014). High levels of GALNT6 have been reported to predict improved survival in pancreatic (Li et al., 2011) and colorectal cancer (Ubillos et al., 2018), but poorer survival in breast (Liu et al., 2020), lung (Song et al., 2020) and ovarian cancer (Lin et al, 2017). Increased expression in bone marrow samples from breast cancer patients predicted subsequent recurrence in lymph node negative patients (Freire et al, 2006). Overexpression of GALNT8 has been reported to be correlated with poor patient prognosis in colorectal cancer (Tang et al., 2021) and, the opposite, downregulation, to be associated with poor outcome in breast cancer (Huang et al., 2022). Increased expression of
GALNT9 has been reported to be associated with improved survival in neuroblastoma (Berois et al., 2013). GALNT10 immunopositivity has been reported to be associated with high grade (Gao et al., 2013) and with lymph node and distant metastases and poor prognosis in gastric cancer (Xu et al., 2020b). GALNT12 levels have been reported to be lower in colorectal cancer cases with metastases (Guo et al., 2004). Increased expression of GALNT13 in patients with advanced stage neuroblastoma correlated with poor outcome (Berois et al., 2006b). High levels of GALNT14 in ovarian cancer were associated with advanced stage (Yang et al., 2016) but with low histological grade in breast cancer (Wu et al. 2010).

There is therefore strong evidence of alterations in expression of most members of the GALNT family in a wide range of cancers, which, in some instances, have been shown to have prognostic significance. However, the situation is not as simple as, for example, an increase in GALNT activity being associated with more or less aggressive cancer behaviour. We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages of the metastatic cascade (Beaman and Brooks, 2014). Recently, we have become aware that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis.

**Epithelial mesenchymal transition in cancer metastasis**

Metastasis, the dissemination of cancer cells from a primary tumour mass to form secondary lesions at distant anatomical sites, accounts for about 90% of cancer patient deaths (Sporn, 1996; Germanov et al., 2006). It is accepted that the most common route by which cancer cells disseminate is through the blood circulation; however, cancer cells may also invade new sites by direct extension into adjacent tissues or may enter the lymphatics and colonise local and regional lymph nodes. There remains some controversy as to whether lymph node metastases represent a
dead end for metastasising cancer cells, and serve only as a clinically useful proxy marker for the
likelihood of further disseminated disease, or whether instead they are a staging post such that
tumours in the lymph nodes can themselves seed further distant metastases (reviewed by
Weinberg, 2007). Either way, metastasis results from a cascade of events which commonly includes
initial tumour angiogenesis, invasion of local basement membrane and local stroma, intravasation
and hematogenous/lymphatic dissemination, attachment to vascular endothelium and
extravasation, and formation of a secondary tumour. Whilst a detailed description of metastasis
goes beyond the scope of the current review, the key stages are illustrated in Figure 3 and it is well
reviewed in the literature (for example, Brooks et al., 2010; Chaffer and Weinberg, 2011; 2015;
Welch and Hurst, 2019). Throughout the metastatic cascade, tumour cells alter their phenotype and
behavioural characteristics to a remarkable degree. These highly plastic changes in cancer cell
morphology and motility involve reactivation of the developmental program termed epithelial-
mesenchymal transition (EMT) and its reversion, mesenchymal-epithelial transition (MET) (reviewed
by Micalizzi et al., 2010; Chaffer et al., 2016; Kim et al., 2017; Lu and Kang, 2019).

EMT is the trans-differentiation of epithelial cells to mesenchymal cells (Hay, 1995), and involves a
number of morphological and molecular changes, summarised in Figure 4. During EMT, epithelial
cells lose their characteristic apical-basal polarity through the dissolution of tight junctions. This
permits the fraternisation of apical and basolateral membrane components, resulting in the end-to-
end polarity associated with mesenchymal cells (Greenburg and Hay, 1982). The structural integrity
of epithelial sheets dissipates through elimination of gap junctions and adherens junctions
(Shtutman et al., 2006). Cell adhesion molecules, including E-cadherin and epithelial-specific
integrins that mediate cell-cell and cell-basement membrane connections, respectively, are replaced
with N-cadherin and αvβ6 integrin, which impart a transient adhesion (Nakajima et al., 2004). In the
process of becoming mesenchymal, cells gain resistance to anoikis (Frisch et al., 2013). The actin
cytoskeleton of epithelial cells is re-structured and substituted with stress fibres, whilst cytokeratin
intermediate filaments are exchanged for vimentin (Micalizzi et al., 2010), resulting in a
morphological change in cells from cuboidal to spindle-shaped (Boyer et al., 1989). Finally, the basement membrane is degraded through the secretion of proteases, and the motile mesenchymal cells are able to invade the extracellular matrix and surrounding stroma (Savagner, 2001).

**Transcriptional regulation of tumour-associated epithelial-mesenchymal transition**

The process of EMT is reviewed in depth by Lamouille et al. (2014). The process is induced in the primary tumour microenvironment by autocrine/paracrine secretion of a number of growth factors, cytokines and extracellular matrix proteins (Tse and Kalluri, 2007; Martin et al., 2010; Jing et al., 2011) produced in response to hypoxia (Jiang et al., 2011) and inflammation (López-Novoa and Nieto, 2009; Zhou et al., 2012). Binding of these EMT-inducing signals to their receptors on the cell surface triggers a myriad of intracellular signalling networks which act pleiotropically to induce EMT transcription factors.

A highly simplified diagram illustrating transcriptional regulation of some of the principle pathways involved in EMT signalling is given in Figure 5. Briefly, at the cell surface, binding of bone morphogenic proteins (BMPs) to their receptors BMPR1/2 activates intracellular SMAD proteins which initiate transcriptional induction of EMT (Frey et al., 2020). Alternatively, upon binding of the cytokine transforming growth factor-beta (TGF-β) to its receptors TGF-βR1/2, intracellular signalling can occur through either SMAD-dependant or -independent pathways (Aashaq et al., 2022). A SMAD-independent pathway is activation of the SRC homology 2 domain-containing-transforming A (SHCA), which creates a docking site for growth factor receptor-bound protein 2 (GRB2) and son of sevenless (SOS) and initiates the RAS-RAF-MEK1/2-ERK1/2 pathway (Zhang, 2009). Binding of growth factors such as epidermal growth factor (EGF) (Ackland et al., 2003), hepatocytpe growth factor (HGF) (Nagai et al., 2011) and insulin-like growth factor (IGF) (Cevenini et al., 2018) to tyrosine kinase receptors can activate the RAS-RAF-MEK1/2-ERK1/2 pathway as well as the P13K-Akt signalling cascade. Binding of Delta or Jagged to Notch receptor activates hairy and enhancer of split 1 (HES1),
inhibits phosphatase and TENsin homolog (PTEN) which is an inhibitor of the PI3K/Akt pathway (Ranganathan et al., 2011). Binding of Wnt to Frizzled (FZD) inhibits glycogen synthase kinase-3β (GSK3β), which in turn stabilises β-catenin so that it can translocate to the nucleus and initiate EMT transcription factors (Wu and Pan, 2010). Akt from the PI3K-Akt signalling pathway can also inhibit GSK3β. Binding of Sonic hedgehog (SHH) to Patched (PTCH) results in a change in structural conformation of the transmembrane protein thereby releasing Smoothened (SMO), which is then able to activate the glioma-associated (GLI) family (Riaz et al., 2019).

These EMT-inducing signals are responsible for the stimulation of EMT core regulators, which are transcription factors that regulate EMT effectors; that is, the proteins that identify cells as being either epithelial or mesenchymal, such as E-cadherin and cytokeratin (epithelial markers) and vimentin and N-cadherin (mesenchymal markers) (reviewed by Tsai and Yang, 2013). EMT core regulators fall into three groups: (1) SNAI1 (snail family transcriptional repressor 1, SNAIL) and SNAI2 (snail family transcriptional repressor 2, SLUG)) (Savagner et al., 1997; Cano et al., 2000; Bolós et al., 2003), (2) ZEB1 and ZEB2 (Comijn et al., 2001; Eger et al., 2005; Xiong et al., 2012) and (3) TWIST1 and TWIST2 (Lo et al., 2007; Vesuna et al., 2008; Casas et al., 2011; Fang et al., 2011). Once these transcription factors have been expressed and activated, each can act pleiotropically to orchestrate the EMT process (reviewed by Sánchez-Tilló et al., 2012).

**Changes in GALNT expression or activity may influence cancer cell behaviour through altered O-glycosylation of many different proteins**

Widespread and diverse alterations in glycosylation of myriad different molecules is reported during EMT, and have sometimes been shown to have a regulatory or functional role, as recently reviewed by Pucci et al., (2021). In the following sections, we will focus specifically on the evidence that GALNTs, through their role in regulating the initiation of O-linked GalNAc glycosylation of a wide variety of proteins, potentially influence EMT, and this may in part explain the association between
changes in GALNT levels and cancer prognosis, described previously. It is important to make the point, however, that a hugely diverse range of proteins passing through the secretory pathway could potentially be modified by the action of GALNTs, and it would be naïve to postulate that the only effect of cellular changes in GALNT levels is directly on EMT. Indeed, since many O-glycosylated proteins are extracellular matrix proteins, signalling molecules, receptors and adhesion molecules, changes in GALNTs might be predicted to influence a range of cellular mechanisms involved in cancer progression by influencing the stability or properties of these molecules (reviewed by Chia et al., 2016).

Using ‘SimpleCell’ technology, Steentoft et al. (2013) identified around 3000 potential GalNAc O-glycosylation sites in 600 proteins produced by cancer cells, which illustrates the potential complexity. Lavrsen et al. (2018) carried out RNAseq analysis of colon cancer cells engineered to express or not express GALNT6 and identified more than 100 genes that were associated with GALNT6 expression, and more than half were involved in cell cycle control, indicating a role in cell proliferation. Moreover, they identified a range of cell adhesion molecules that were upregulated with GALNT6 knockdown, including P-cadherin, cadherin-17, CD44 and versicon, and GALNT6 expression decreased cell adhesion in a cell dissociation assay. But in their study, they found no evidence that cells expressing GALNT6 had altered levels of EMT-associated markers (E-cadherin, N-cadherin, vimentin, fibronectin) or inducers (SNAIL, SLUG, TWIST or TGF-β), implying that GALNT6 expression alone did not induce EMT in colon cancer cells. This study therefore provides clear evidence that expression of GALNT6, which is a feature of colon cancers but not of normal colonic epithelium, resulted in loss of cell differentiation and adhesion, and increased cell proliferation, which might contribute to malignant progression and indirectly influence EMT, but did not directly contribute to EMT. Added to this, there are many studies that implicate GALNTs in contributing to cell growth (for example, Peng et al., 2012; Li et al., 2012; Ding et al., 2012; Wang et al., 2014) and immune evasion (for example, Adachi et al., 1997; Gaziel-Sovran et al 2011), which could contribute to tumorigenesis by mechanisms other than by inducing EMT.
It is also important to recognise that few of the studies cited in the following sections explored site specific O-glycosylation mediated by the GALNTs. Our broader knowledge of the precise function of site specific O-glycosylation of specific proteins still remains quite limited, largely because of how technically complex it is to investigate. However, established functions include protecting proteins from proteolytic cleavage, stabilising domain structures, and modulating binding affinity and receptor function. This rapidly expanding field was recently reviewed by Wandall et al. (2021), and they emphasised how occupancy of a single O-glycosylation site may offer highly specific and dynamic regulation of protein function. Some representative examples of where function of site specific O-glycosylation has been well studied and is established include GALNT3 glycosylation of fibroblast growth factor 23 contributing to familial tumoral calcitosis, and GALNT2 glycosylation of angiopoietin like-3 protein contributing to high serum triglyceride and high-density lipoprotein cholesterol levels, implicated in cardiovascular disease (reviewed by Chia et al., 2016; Wandall et al., 2021).

**GALNTs alter GAINAc O-glycosylation of signal induction receptors and signal transduction pathways involved in EMT**

The strongest evidence of GALNT expression regulating EMT comes from reports where GALNTs have been demonstrated to act on EMT signal induction receptors. These studies have often demonstrated altered levels of GALNTs in clinical samples of various cancers, then explained this relationship by demonstrating the effects of GALNT overexpression and/or knockdown on cell proliferation, and on cell migration and invasion. Many studies have also sought to demonstrate that GALNT expression results in either a general increase in GalNAc O-glycosylation of proteins or of increased GalNAc O-glycosylation of specific EMT-related molecules.
Huang et al. (2015) explored GALNT1 and hepatocellular carcinoma. They first demonstrated that GALNT1 levels were often elevated in hepatocellular carcinoma, and that this correlated with decreased overall patient survival. They showed that GALNT1 O-glycosylates EGFR. Whilst they detected no decrease in Tn antigen on EGFR after GALNT1 knockdown using VVA labelling, treating the cells with benzyl-α-GalNAc, which inhibits O-linked chain extension, did result in an increase in VVA labelling – signifying that GALNT1 knockdown resulted in a decrease in more extended O-glycans on EGFR. GALNT1 knockdown also increased EGFR degradation and decreased its activation, leading to decreased hepatocellular carcinoma cell migration and invasion.

Similar findings have been presented in several studies of other GALNTs, and in a range of cancers. Wu et al. (2011) found that GALNT2 was downregulated in hepatocellular carcinomas in comparison to adjacent normal tissue, and downregulation was most common in patients with vascular invasion and evidence of recurrence. Over-expression of GALNT2 in cell lines suppressed their invasive and migratory potential and the growth of xenografts in mice. VVA pulldown and western blot demonstrated that EGFR was O-glycosylated by GALNT2. Lin et al. (2014) demonstrated that GALNT2 was detectable by immunohistochemistry in high-grade oral squamous carcinoma tissues, and was localised at the invasive edge of tumours. GALNT2 overexpression in oral squamous carcinoma cells enhanced their invasion and migration. Furthermore, GALNT2 knockdown decreased VVA binding to EGFR and EGF-induced phosphorylation of EGFR and Akt, and overexpression enhanced them, indicating that GALNT2 O-glycosylates EGFR. Sun et al. (2019) also explored GALNT2, this time in glioma. Again, they demonstrated that GALNT2 immunopositivity was associated with high grade, poor prognosis gliomas. GALNT2 overexpression in glioma cell lines resulted in increased phosphorylation of EGFR, and an increase in its glycosylation by Tn antigen, determined by western blot and VVA lectin pull-down assays, and influenced the expression of p21, cyclin-dependent kinase 4 (CDK4), cyclinD1, MMP-2 and-9 through the EGFR/PI3K/Akt pathway, as well as enhancing cell
invasion and migration. Knockdown achieved the opposite effects. Moreover, GALNT2 silencing resulted in less aggressive tumours in a mouse model, with reduced cellular proliferation and MMP2 expression. Confusingly, Hu et al. (2018) reported contradictory results in gastric cancer cells. They reported that GALNT2 knockdown resulted in decreased Tn antigen on EGFR, determined by VVA pulldown, but also enhanced, rather than reduced, its phosphorylation, and also the phosphorylation of Akt. This was associated with enhanced migration and invasion, which was abrogated by the addition of an EGRF inhibitor or an Akt inhibitor.

Xu et al. (2021) reported that upon GALNT3 knockdown in ovarian cancer cells, levels of phosphorylated PI3K and phosphorylated Akt decreased, suggesting that GALNT3 activated the PI3K/Akt pathway. Moreover, they demonstrated that the microRNA miR-378a-3p suppressed the expression of PI3K and pAkt, which could be rescued by GALNT3. Further, they showed that miR-378a-3p binds to the 3’UTR of GALNT3 which degrades GALNT3 and suppresses its translation. Taken together, these findings suggest a role of GALNT3 in activation of the EMT-associated PI3K/Akt signalling pathway.

Lin et al. (2017) demonstrated that elevated levels of GALNT6 correlate with lymph node and distant metastasis and reduced survival in ovarian endometrioid and clear cell carcinomas, and provided evidence that this was through altered EGFR signalling, in studies reminiscent of those cited previously exploring GALNT2. Knocking down GALNT6 in epithelial ovarian cancer cells significantly reduced their mesenchymal-like properties of cellular migration and invasion, and did so by decreasing phosphorylation of EGFR, whilst VVA pull down confirmed that GALNT6 glycosylated EGFR with Tn antigen. Liu et al. (2020) also investigated GALNT6, this time in breast cancer. They showed that survival of breast cancer patients with tumours expressing high levels of GALNT6 was shorter than those with tumours expressing low levels. In cell lines, knock down of GALNT6 inhibited PI3K/Akt signalling, and this was further suppressed by the knockdown of alpha 2 macroglobulin (α2M); the opposite was observed when GALNT6 and α2M were overexpressed. They
describe α2M as a substrate of GALNT6 and propose that GALNT6 mediates O-glycosylation, and therefore stabilisation, of the α2M-activated PI3K-Akt signalling pathway in breast cancer. VVA pulldown indicated that GALNT6 knockdown reduced the amount of exposed Tn antigen present on breast cancer cells. Breast cancer cells over-expressing GALNT6 showed enhanced migratory and invasive behaviour, and those where GALNT6 was knocked down showed reduced migratory and invasive potential, indicating that GALNT6 can drive these EMT-like behaviours through the mechanisms identified.

Cao et al. (2020) demonstrated that miR-125a-5p, which has been reported to be reduced in cancer tissues in comparison to normal, directly binds to the GALNT7 gene, repressing its expression. Moreover, they provided evidence that GALNT7 promotes cervical cancer cell proliferation and invasion in a matrigel assay by activating the EGFR/PI3K/Akt pathway. This was confirmed in a mouse xenograft model where GALNT7 suppression resulted in smaller tumours. It would be reasonable to assume that the effect of GALNT7 may be through O-glycosylation and phosphorylation of EGFR, as reported above, although this was not directly assessed in the study, and, in common with the studies cited above, classical markers of EMT, such as E-cadherin and vimentin were not examined.

Supporting evidence for the role of GALNT family members in this mechanism was also provided by Li et al. (2021), who demonstrated that downregulation of GALNT14 in ovarian cancer cells significantly decreased Tn antigen glycosylation of EGFR, detected through VVA pull down. They showed that this reduced the stability of EGFR, shortened its half-life and subsequently inhibited the EMT-related EGFR/PI3K/Akt signalling pathway, although the authors did not specifically address EMT or the migratory or invasive behaviour of the cells. Instead their focus was on identifying that GALNT14 contributes to enhancing the cytotoxic action of cisplatin through glycosylating and stabilising EGFR.
Comparable evidence has been reported regarding GALNT glycosylation of type 1 insulin-like growth factor receptor (IGFR) influencing the activation of the IGF/PI3K/Akt signalling pathway. Ho et al. (2014) reported that increased GALNT2 immunoreactivity predicted early stage and favourable prognosis in neuroblastoma patients, and GALNT2 over expression resulted in smaller tumours in mice. Overexpression of GALNT2 in neuroblastoma cells resulted in increased O-glycosylation of IGFR with Tn antigen, as evidenced by VVA pull down. This prevented IGFR dimerization and subsequent downstream signalling, resulting in reduced cell growth, and reduced migration and invasion in transwell and matrigel assays.

In contrast, Liu et al. (2016) demonstrated that GALNT2 protein and mRNA were reduced in human gastric cancer samples, and that reduced GALNT2 was associated with advanced disease and shorter recurrence free survival. Knockdown of GALNT2 in gastric cancer cells increased their proliferation, and also their migration and invasion in transwell and matrigel assays. GALNT2 knockdown also promoted metastasis in a mouse model. GALNT2 knockdown in gastric cancer cells enhanced phosphorylation and reduced Tn antigen on hepatocyte growth factor receptor (HGFR, tyrosine protein kinase Met, or c-Met), as evidenced by reduced VVA binding. The authors propose that GALNT2 suppresses the malignant potential of gastric cancer cells through exposure of truncated O-glycans, including Tn antigen, dysregulating HGFR activation and inhibiting HGF/PI3K/Akt signalling.

The Notch/HES1-PTEN-PI3K/Akt signalling pathway

Wang et al. (2021) reported that GALNT2 expression in lung adenocarcinoma correlated with poor patient prognosis. Moreover, GALNT2 increased the ability of lung cancer cells to form colonies, migrate in a wound healing assay and invade matrigel by activating the Notch/HES1-PTEN-PI3K/Akt signalling pathway. They observed that Notch1, -2, -3 and -4 are co-expressed with GALNT2 in lung cancer and confirmed using western blot that GALNT2 expression elevated Notch1 and -3 levels. The downstream molecules of the Notch signalling pathway, HES1 and -5, were also elevated. HES1
inhibits the tumour suppressor PTEN, which actively blocks the PI3K/Akt signalling pathway. They further demonstrated that by knocking down GALNT2, PTEN expression increased and the downstream signalling molecules decreased. The opposite was found with a cell line that was engineered to overexpress GALNT2. It is reasonable to assume that GALNT2 O-glycosylation stabilises Notch, subsequently activating HES1, thereby inhibiting PTEN and activating the PI3K/Akt signalling pathway. Indeed, the authors speculate that GALNT2 acts to glycosylate and therefore stabilise Notch, but note that they plan to investigate this in further work. Wu et al. (2021a) reported conflicting findings in relation to GALNT4 and breast cancer. They showed that analysis of patient datasets indicated that high GALNT4 was associated with enhanced, rather than reduced, recurrence free survival. Knockdown in breast cancer cell lines increased cell proliferation and the authors concluded, through comparison of differentially expressed genes in knockdown versus wild type cells, that this was through activation of Notch signalling pathway.

The TGF-β signalling pathway

Maupin et al. (2010) specifically sought to identify glycosylation-related genes associated with EMT by examining pancreatic cancer cells lines in three different model systems: (a) direct induction of EMT by treatment with TGF-β (b) classifying the morphologies of cancer cell lines as epithelial-like or mesenchymal-like and (c) an assay of cell migration where cells were seeded into a defined area and allowed to migrate for a set time period. Expression data from a list of 587 genes involved in glycosylation were analysed. The authors identified a number of ‘glycogenes’ that correlated with EMT-related behaviours in these models, including GALNT2 and GALNT10, which were increased in TGF-β-induced EMT, and GALNT13 which showed higher expression in migratory cells. What role(s) GALNTs play in TGF-β-induced EMT is unclear, however it would be reasonable to speculate that they would be performing a stabilising role, thereby preventing proteolysis, through O-glycosylating proteins that are involved in the TGF-β signalling cascade. Evidence from Freire-de-Lima et al. (2011),
described later, indicates that O-glycosylation of the extracellular matrix protein fibronectin may also be implicated.

It is interesting that Wu et al. (2021b) reported converse findings when they examined the relationship between GALNT4 and EMT in breast cancer cells. Having demonstrated that GALNT4 was upregulated in good prognosis, luminal type breast cancer and associated with favourable recurrence free survival, they showed that knockdown of GALNT4 was associated with mesenchymal cell morphology and over-expression with an epithelial phenotype. They also correlated GALNT4 knockdown with a decrease in classical epithelial marker E-cadherin, and increase in mesenchymal markers N-cadherin and SNAIL, and overexpression with the opposite. These findings correlated with cell behaviour in wound healing and invasion assays. Upon treatment with TGF-β, EMT was enhanced in GALNT4 knockdown cells and suppressed in cells where GALNT4 was over-expressed. GALNT4 activity was associated with O-glycosylation of TGF-β type I and type II receptors, including their glycosylation with Tn antigen assessed by VVA binding, and this led to decreased TGF-β dimerization and activity. Using an HPLC-based in vitro O-glycosylation system followed by experiments where specific residues were mutated, they were able to identify Ser 31, corresponding to the extracellular domain of TGF-β type II receptor, as being the O-glycosylation site of GALNT4. Intriguingly, GALNT4 was shown to have a higher affinity for the potential glycosylation site on the TGF-β type II receptor site than the ubiquitously expressed GALNT2. These findings suggest a further layer of complexity in the regulation of the EMT process exerted by GALNTs.

**BMP4/SMAD1 EMT activation**

Huang et al. (2022) provided evidence of GALNT8 being involved in regulation of EMT activation in breast cancer through the BMP4/SMAD1 pathway. The focus of their study was to seek evidence of GALNT8 having a role in regulating estrogen receptor-α (ER-α) through BMP signalling in breast cancer. Levels of GALNT8 were assessed in publicly available breast cancer datasets, and a clear
relationship between GALNT8 downregulation, poor clinical outcome and lower ER-α expression was apparent. The relationship between downregulation of GALNT8 and reduced levels of ER-α was confirmed by immunohistochemistry of tissue samples, and in a series of breast cancer cell lines. Manipulating expression of GALNT8 resulted in changes in proliferative rate of the cells, with overexpression reducing proliferation, and knockdown enhancing it. That this was mediated through ER signalling was demonstrated through use of an ER inhibitor. However, EMT-related cell behaviour or markers of EMT were not directly assessed. Introducing a BMP/SMAD activator or inhibitor resulted in alterations in GALNT8 levels. VVA pulldown and assessment of the effects of mutating potential O-glycosylation sites of BNPR1A indicated O-GalNAc glycosylation of BNPR1A by GALNT8. Taken together, the results suggest that GALNT8 O-glycosylates BNPR1A, thus activating the BMP4/SMAD1 pathway.

Xu et al. (2020b) focussed on a different player in the BMP4/SMAD1 pathway, HOXD13. They showed that high levels of GALNT10 in gastric cancer clinical samples, as determined by qRT-PCR, were associated with lymph node and distant metastases and poor prognosis. They demonstrated that knocking down GALNT10 in gastric cancer cells reduced their proliferative activity and their invasive potential in a transwell migration assay. Bioinformatics analysis that suggested that GANT10 could combine with HOXD13 were confirmed in a dual-luciferase reporter gene experiment, which verified that HOXD13 could directly target GALNT10. These data suggest that that GALNT10 O-glycosylates and stabilises HOXD13, and that this promotes EMT-like migratory behaviour, although EMT was not specifically assessed in this study. Confusingly, contradictory evidence was provided by Xue et al. (2021) who showed that HOXD13 prevents BMP4/SMAD1 EMT activation, and therefore inhibits EMT, in prostate cancer cells. HOXD13 was demonstrated to directly bind to the SMAD1 promoter and suppress SMAD1 transcription. HOXD13 overexpression blocked BMP4/SMAD1-induced EMT, assessed by protein levels and gene expression of E-cadherin and fibronectin after BMP4 treatment, and knockdown of HOXD13 resulted in prostate cancer cells becoming more invasive and migratory. Moreover, in analysis of patient datasets,
decreased HOXD13 expression was significantly associated with early recurrence. However, this study did not consider GALNTs or HOXD13 glycosylation directly.

**GALNTs directly or indirectly modulate EMT effectors**

A number of studies provide evidence that GALNT activity directly or indirectly modulates the expression of classical EMT effectors, including the epithelial marker E-cadherin and the mesenchymal marker vimentin. Song et al. (2020) showed that GALNT6 immunopositivity was associated with lymph node metastasis and poor prognosis in lung adenocarcinoma. They went on to demonstrate that knockdown of GALNT6 in lung adenocarcinoma cell lines increased the expression of E-cadherin and reduced the expression of N-cadherin and SLUG; conversely, overexpression of GALNT6 decreased E-cadherin and increased N-cadherin and SLUG. These changes were associated with changes in the cells migratory and invasive potential in a wound healing assay, and GALNT6 silencing resulted in reduced metastatic potential in a mouse xenograft model. By immunoprecipitation studies followed by VVA labelling of western blots, they showed that GALNT6 O-glycosylated and stabilised glucose-regulated protein 78 (GRP78), an endoplasmic reticulum-based molecular chaperone which promotes the folding and oligomerization of proteins. Over expression of GRP78 caused relocation of GALNT6 to the endoplasmic reticulum, potentially increasing initiation of GalNAc O-glycosylation and synthesis of Tn antigen through the GALA pathway, and also increased phosphorylation of ERK1/2. Knockdown of GALNT6 decreased expression of both GRP78 and ERK1/2, thus contributing to modulation of MEK1/2/ERK1/2 signalling.

Raghu et al. (2019) demonstrated that loss of GALNT3 was associated with a mesenchymal phenotype in breast cancer cells and in trophoblast stem cells. In trophoblast stem cells, which were the main focus of the study, GALNT3 knockdown was associated with reduced E-cadherin and increased vimentin, as well as other EMT markers that were investigated, and induction of EMT transcription factors TWIST, ZEB1, and SLUG. It also increased motility and invasiveness of cells. Re-
expression of GALNT3 restored the epithelial phenotype. GALNT3 was demonstrated by VVA labelling to O-glycosylate E-cadherin with Tn antigen, and knockdown resulted in E-cadherin being retained it in the Golgi apparatus, rather than expressed at the cell surface, thus contributing to EMT. Interestingly, Balcik-Ercin et al. (2018) reported that ZEB2 also binds to, and represses, GALNT3.

Ectonucleotide pyrophosphatase 1 (ENPP1) normally plays a role in regulating cell signalling response to insulin. Marucci et al. (2013) reported that GALNT2 knockdown in human liver cancer cells increased ENPP1 expression, decreased insulin-induced insulin receptor beta subunit phosphorylation, and also reduced Akt phosphorylation and therefore signalling. They demonstrated that GALNT2 bound to ENPP1-3′UTR mRNA and inhibited ENPP1 transcript and protein expression. The authors speculate that GALNT2 may also alter the O-glycosylation of ENPP1, but they did not directly explore this in their study. Hu et al. (2019) provided evidence that ENPP1 also functions to induce an EMT phenotype in lung cancer cells. Knocking down ENPP1 repressed E-cadherin and vimentin. Consistent with this, Detarya et al. (2020) demonstrated that knocking down GALNT5 inhibited EMT in cholangiocarcinoma cells and reduced their proliferation, invasion and migration, by inactivating Akt/ERK signalling.

**GALNTs influence glycosylation of EMT-associated mucins**

Overexpression of mucins (MUCs) has been demonstrated to promote tyrosine kinase signalling, activate growth and survival pathways, including the Wnt/β-catenin EMT signalling pathway, and induce loss of epithelial cell polarity (reviewed by Kufe, 2009). They are therefore of interest as attractive targets for the development of anti-cancer antibodies and drug inhibitors. MUCs are a large family of highly O-glycosylated glycoproteins (Corfield, 2015; Dhanisha et al., 2018). Several members MUC family, including MUC1, -4 and -13, are reported to be frequently over-expressed in cancers and are related to poor prognosis and metastasis (for example, Taylor-Papadimitriou et al.,
1999; Gendler, 2001; Carraway et al., 2009; Chauhan et al., 2009; Sousa et al., 2016; He et al., 2017; Kumari et al., 2018; Syrkina et al., 2019). It is well accepted that dense clustering of O-glycans on mucins contributes to their structural support and protection from degradation, and aberrant glycosylation of mucins, particularly with truncated O-glycans such as Tn antigen, have been reported to influence their stability and subcellular localisation (Altschuler et al., 2017).

Ponnusamy et al. (2010) provided clear evidence that one member of the family, MUC4, was able to upregulate N-cadherin, and thereby drive metastasis in ovarian cancer cells through EMT. Expressing MUC4 in ovarian cancer cells resulted in a dramatic change in their morphology, from adhesive and epithelial to spindle-shaped with reduced cell-cell contact and the presence of obvious filopodia, lammelopodia and microspikes. E-cadherin was decreased, whilst N-cadherin, vimentin, TWIST1, TWIST2 and SNAIL were increased. They went on to demonstrate that MUC4 expression activated Akt and ERK1/2 signalling, and that ERK1/2 phosphorylation also upregulated expression of MMP-9. Induction of MUC4 resulted in ovarian cancer cells being more metastatic in a mouse model. Whilst this study did not address MUC glycosylation, it clearly demonstrates the potential for members of the MUC family to induce EMT. Evidence from other studies have directly related GALNT and MUC expression to EMT. These studies all suggest a regulative role of GALNT expression, where upregulation of a specific GALNT acts to glycosylate and stabilise a member of the MUC family, resulting in altered expression of cell adhesion molecules and the subsequent transition towards a more mesenchymal-like phenotype and dissemination from the primary tumour mass.

A good example is the study by Wang et al. (2014) who identified increased levels of GALNT3 in epithelial ovarian cancer tissues in comparison to normal, where it was associated with shorter recurrence free survival. Knockdown in epithelial ovarian cancer cells led to reduced proliferation, invasion and migration. They carried out gene expression profiling and network and pathway analysis and found that numerous genes and pathways implicated in ovarian tumorigenesis, invasion and metastasis were downregulated upon GALNT3 suppression, while some tumour suppressor
genes were induced. GALNT3 downregulation also resulted in reduced MUC1 protein expression and they hypothesised that this was due to reduced O-glycosylation resulting in its destabilization and subsequent proteolysis of MUC1 protein due to lack of GALNT3 glycosylation activity, although this was not directly demonstrated. GALNT3 knockdown was also associated with an increase in the epithelial associated cell adhesion molecules, β-catenin and E-cadherin after GALNT3 knockdown, and the authors concluded that these molecules are normally suppressed by MUC1 in cancer, supporting a role for GALNT3/MUC1 in promoting cancer cell invasion through EMT.

Park et al. (2010) made similar observations concerning GALNT6 in breast cancer. Immunohistochemistry showed that GALNT6 was strongly detectable in breast cancers but not in normal breast. Knockdown of either GALNT6 or MUC1 in breast cancer cells resulted in a change in their morphology to a more epithelial, rounded shape and enhanced proliferation. Moreover, knockdown of GALNT6 resulted in a reduction in MUC1 protein and over-expression to an increase, indicating that they are co-expressed. Knockdown of GALNT6 also resulted in an increase in epithelial markers E-cadherin and β-catenin. An in vitro GalNAc transferase assay and VVA lectin blotting both confirmed that GALNT6 O-glycosylates MUC1. The authors propose that upregulation of GALNT6 stabilises MUC1 through its glycosylation activity, and MUC1 then interacts cell adhesion molecules such as β-catenin and E-cadherin, resulting in the anti-adhesive effect. The same group (Tarhan et al., 2016) reported that knocking down GALNT6 in pancreatic cancer cells reduced the expression of MUC4 and EGFR2. It also resulted in an alteration in cell morphology from elongated and mesenchymal-like to epithelial-like, and switched cadherin expression from P-cadherin to E-cadherin, and reduced cell invasiveness in a transwell assay. GALNT6 was demonstrated to O-glycosylate MUC4 in an in vitro glycosylation assay, presumably resulting in its stabilisation, and the Thr residue within a peptide fragment that was the predominant target of GALNT6-mediated O-glycosylation was identified by MALDI-TOF mass spectrometry. It had previously been reported that MUC4 knockdown enhanced formation of an E-cadherin/β-catenin complex resulting in the
Consistent with these observations, Wang et al. (2013) reported that knockdown of GALNT14 in epithelial ovarian cancer cells resulted in a morphological change from elongated and mesenchymal-like to rounded and epithelial-like, and the migratory capacity of the cells in a wound healing and transwell migration assay also decreased. They demonstrated that GALNT14 O-glycosylates MUC13 by assessing VVA binding to MUC13 in western blots before and after GALNT13 knockdown, and proposed that this effect was through reduced O-glycosylation, and subsequent destabilisation, of the MUC13 protein by GALNT14, in a manner analogous to that proposed regarding MUC1 and MUC4. Moreover, they demonstrated that an inhibitor of ERK1/2 suppressed the expression of GALNT14 and reduced Tn antigen levels as assessed by VVA binding.

To add a further level of complexity, Caffrey et al. (2019) demonstrated that in pancreatic cancer, the MUC1 cytoplasmic tail binds to regulatory elements in the GALNT5 gene, thus downregulating its expression, and moreover that levels of MUC1 and GALNT5 were inversely correlated in pancreatic cancer tissues. This suggests that in some instances there may be a reciprocal regulatory process occurring between the GALNTs and MUCs that may also contribute to the EMT process.

**GALNTs modulate the extracellular matrix and MMPs, as well as EMT markers**

A number of studies have shown that GALNT activity, in addition to driving EMT through the various mechanisms described above, can also have a parallel effect on modifying the cancer-related stroma, thus potentially further facilitating cancer cell motility and invasion. GALNT6, for example, has been shown in several studies, cited earlier, to drive EMT in epithelial ovarian cancer (Lin et al., 2017), pancreatic cancer (Tarhan et al., 2016) and breast cancer (Park et al., 2010). GALNT6 has also been shown to modulate the breast cancer-associated stroma. Expression of fibronectin, a key

...
extracellular matrix glycoprotein, has been shown to be increased in EMT-associated processes such as wound healing (reviewed by Lenselink, 2015) and embryonic development (de Almeida et al., 2016) and is a prominent feature of breast cancer stroma (Park and Schwarzbauer, 2014; Li et al., 2019). In order for fibronectin fibrils to be assembled, cellular contractile forces are required, which stretch compact fibronectin dimers thereby exposing a cryptic heparin-binding region. Crucially, this domain binds many soluble EMT growth factors, including TGF-β1 (Griggs et al., 2017). Park et al. (2011) demonstrated that GALNT6 O-glycosylates, and thereby stabilises, fibronectin thus preventing its degradation and presumably allowing assembly into fibrils and subsequent exposure of the growth factor binding site. They also reported that overexpression of GALNT6 in a normal breast epithelial cell line resulted in a change in morphology from rounded and epithelial-like to elongated and mesenchymal-like, accompanied by a reduction in the epithelial marker E-cadherin and increase in the mesenchymal marker N-cadherin. Overexpression of GALNT6 also resulted in a disruption in the formation of an acinar morphology when the cells were grown in three dimensional culture, and invasive behaviour in Matrigel. GALNT6 expression is clinically associated with poor prognosis in breast cancer (Liu et al., 2020). These results are supported by those of Freire-de-Lima (2011), described briefly earlier, who set out to specifically examine GalNAc O-linked glycosylation during TGF-β-induced EMT, this time in prostate cancer cells. They identified that under TGF-β stimulation, oncofetal fibronectin was O-glycosylated at a specific Thr in its IIICS domain, and this was associated with a change from epithelial to fibroblastic morphology, enhanced cell motility, decreased expression of the epithelial cell marker, E-cadherin, and enhanced expression of mesenchymal markers. Moreover, knockdown of GALNT6 and GALNT3 inhibited TGF-β-induced EMT up-regulation of oncofetal fibronectin and the EMT process.

Yang et al., (2016) demonstrated that GALNT14 suppression, mediated by miR-125a, was associated with reduced invasive capacity of ovarian cancer cells, and also reduced MMP-2 and -9 activity. Consistent with this, GALNT14 was shown to be upregulated in clinical samples, and this correlated
with reduced levels of miR-125a, and also with advanced disease stage. Consistent with these observations, Huanna et al. (2015) showed that over-expression of GALNT14 in breast cancer cells increased their motility and their ability to invade extracellular matrix, and GALNT14 knockdown had the opposite effect. Increased GALNT14 was also associated decreased mRNA and protein levels of the epithelial marker E-cadherin, and increased levels of the mesenchymal markers N-cadherin and vimentin, as well as VEGF and TGF-β, and the opposite was seen in GALNT14 knockdown cells. The shift to a more mesenchymal and invasive phenotype was associated with increased MMP-2 activity. Using a luciferase assay, the authors attempted to determine whether GALNT14 upregulates MMP-2 by activating its transcription, and to identify the possible AP-1 and E1F-1 sites in the GALNT14 promoter. Results indicated that the AP-1 element is critical in achieving induction of the MMP-2 promoter, whilst E1F-1 is not. Zuo et al. (2018) went on to demonstrate, through VVA labelling of western blot, that GALNT14 glycosylates multiple proteins, including EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2) with Tn antigen and stabilises it, and this increases the invasive capacity of breast cancer cells.

Relocation of GALNT1 to the endoplasmic reticulum in liver cancer cells through the GALA pathway, described earlier, was reported by Nguyen et al. (2017) to result in increased GalNAc O-glycosylation of MMP-14, which was determined using a number of methods. These included VVA pulldown and western blot, and metabolic labelling with an azide-modified analogue of GalNAc, GalNAz. Also, to determine the presence of more extended O-glycans, VVA pulldown after neuraminidase treatment of MMP-14 from cells where Cosmc had been knocked down was performed, in addition to pulldown and western blot analysis using lectins from peanut and Datura stramonium. The GALNT1-glycosylated form of MMP-14 facilitated increased tumour growth and metastatic ability of the cancer cells in a mouse model, associated with enhanced extracellular matrix degradation and increased capacity to invade into nearby organs, in comparison to cancer cells expressing the Golgi apparatus located form. The authors confirmed previous reports that MMP14 was O-glycosylated within the hinge domain because mutants deficient in this domain showed reduced glycosylation.
Taken together, these observations point to a complex interplay between regulation of glycosylation, through GALNT expression, controlling EMT and also mediating the integrity of the stroma surrounding the tumour, further contributing to invasion and metastasis.

**Conclusions**

Glycosylation of proteins may influence their binding properties, activity, expression level, and stability. The interplay of the multiple members of the GALNT family contribute to subtle and fine control of GalNAc O-glycosylation of proteins. There are numerous reports in the literature of the normal fine control of GALNTs being dysregulated in a wide range of cancers, and this would be predicted to dramatically alter GalNAc O-glycosylation of a diverse range of proteins, potentially influencing cancer cell biology significantly. Changed levels of GALNT expression or activity have been clearly and repeatedly associated with altered cancer prognosis in humans and tumour behaviour in animal models. Moreover, the clear functional effect of over-expression or knockdown of specific GALNTs in cancer cells leading to profound changes in their behaviour, including migration and invasion, clearly points to their glycosylating, and thereby altering the function of, molecules implicated in epithelial-mesenchymal transition, the process by which stationary, adhesive epithelial cancer cells undergo dramatic transformation to become mesenchymal, motile and invasive. In many instances, studies have provided strong evidence of global changes in GalNAc O-glycosylation as a result of GALNT expression, and often that specific molecular players in the complex process of EMT are glycosylated by the GALNT under scrutiny. However, what is often missing is analysis of the glycan structures produced and, critically, of site-specific glycosylation. What is clear is that GALNTs are master regulators of GalNAc O-linked glycosylation and that their dysregulation in cancer has a profound effect on cancer cell behaviour through, amongst other mechanisms, altering glycosylation and therefore properties of the myriad players in the complex mechanisms of EMT. Further exploration of the specifics of their action and effect may open up new avenues for a better
understanding of cancer biology and therefore, potentially, development of more effective interventions.
List of Abbreviations

BMP: Bone morphogenic protein
BMPR: Bone morphogenic protein receptor
C1GALT1: β1,3 galactosyltransferase or core 1 synthase
C3GnT: β1,3GlcNAc-T, core 3 synthase
EFEMP2: epidermal growth factor-containing fibulin-like extracellular matrix protein 2
EGF: Epidermal growth factor
EGFR: Epidermal growth factor receptor
EMT: Epithelial mesenchymal transition
ENPP1: Ectonucleotide pyrophosphatase 1
ERK: Extracellular signal-regulation kinase
FZD: Frizzled
Gal: galactose
Glc: glucose
GALA: GalNAc-T activation
GalNAc: N-acetylgalactosamine
GALNT: UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferase (also known as
ppGalNAc-T, GalNAc-T)
GlcNAc: N-acetylgalactosamine
GLI: glioma-associated
GRB2: growth factor receptor-bound protein 2
Hes 1: Hairy and enhancer of split 1
HGF: hepatocyte growth factor
HOXD13: Homeobox D13
IGF: insulin-like growth factor
α2M: Alpha-2 macroglobin
MALDI-TOF

MET: Mesenchymal epithelial transition

MUCs: Mucins

PI3K: Phosphoinositide 3-kinase

PTCH: patched

PTEN: Phosphatase and TENsin homolog

q-PCR: quantitative polymerase chain reaction

RT-PCR: reverse transcription polymerase chain reaction

Ser: Serine

SHCA: SRC homology 2 domain-containing-transforming A

SHH: sonic hedgehog

SMAD: Suppressor of mothers against decapentaplegic

SMO: smoothened

SNP: Single nucleotide polymorphism

SOS: son of sevenless

TGF-β: Transforming growth factor-beta

Thr: Threonine

Tn: Thomsen nouvelle

UDP: Uridine diphosphate

VVA: *Vicia villosa* agglutinin

Wnt: Wingless-related integration site

ZEB1: Zinc finger E-box-binding homeobox 1

ZEB2: Zinc finger E-box-binding homeobox 2
References


Chia J, Tham KM, Gill DJ, Bard-Chapeau EA, Bard FA. 2014. ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration. *Elife.* 3:e01828


38


Legends to Figures (figures appended at end)

**Figure 1.** Phylogenetic tree depicting the evolutionary divergence of the GALNT family from the hypothesised ancestral GALNT gene. GALNTs with * are termed sub-family Y and have been proposed to act as chaperones for the other GALNT family members. Adapted from Bennett et al. (2012).

**Figure 2.** Schematic representation of the shared type II membrane structure of the GALNTs. The luminal portion consists of a catalytic domain, a ricin-like lectin domain and a variable length stem region. They are held in place by a hydrophobic transmembrane domain followed by a short N-terminal tail. Adapted from Beaman and Brooks (2014).

**Figure 3.** The sequence of events in metastasis. (1) Angiogenesis, the development of tumoural blood supply. (2) Dissemination of cancer cells from the primary tumour mass by invasion of local basement membrane and migration through stroma. (3) Intravasation of cancer cell into a blood (or lymphatic) vessel followed by (4) hematogenous (or lymphatic) dissemination, where, in the case of hematogenous dissemination, the cancer cells can form rafts with platelets and white blood cells. (5) Adhesion to the vascular endothelium. (6) Extravasation out of the blood (or lymphatic) vessel. (7) Invasion through stroma. (8) Formation a secondary tumour, where (1) angiogenesis is induced again. Cancer cell plasticity through EMT/MET is a feature of multiple stages during metastasis. In the primary tumour, cancer cells will be epithelial-like; to be able to detach from the primary tumour mass, the cell transdifferentiates to mesenchymal-like. The mesenchymal-like cancer cell can invade through basement membrane, surrounding stroma and then intravasate into a blood (or lymphatic) vessel. During haematogenous (or lymphatic) dissemination, the cancer cell transdifferentiates into epithelial-like and can adhere to the endothelium and initiate extravasation. The epithelial-like
cancer cell transdifferentiates into mesenchymal-like allowing it to invade the local stroma and migrate to a secondary site. At the secondary site, the mesenchymal-like cancer cell transdifferentiates into epithelial-like and can give rise to a secondary tumour.

**Figure 4.** During epithelial mesenchymal transition (EMT), epithelial cells down-regulate cell-cell adhesion structures. Loss of adherins junctions and tight junctions alter the cell polarity from apico-basal to anterior-posterior, changing the cell morphology from cuboidal to spindle-shaped, and allowing apical and basolateral membrane components to merge. The actin cytoskeleton is transformed into stress fibres which accumulate at cell protrusions. Epithelial intermediate filaments, the cytokeratins, are replaced by vimentin. The basement membrane is dissolved allowing motile mesenchymal cells to invade the surrounding stroma. Cells become resistant to anoikis. Epithelial-specific markers including E-cadherin are replaced by mesenchymal N-cadherin and αvβ6 integrin. The process is reversible, with motile mesenchymal cells reverting to stationary, adhesive epithelial cells, termed mesenchymal epithelial transition (MET).

**Figure 5.** Transcriptional regulation of tumour associated epithelial mesenchymal transition (EMT): EMT is induced by autocrine/paracrine secretion of growth factors, cytokines and extracellular matrix proteins, which are secreted in response to hypoxia and inflammation. Binding of these EMT inducing signals to their specific receptors on the cell surface triggers a myriad of intracellular signalling networks which can act pleiotropically to induce EMT transcription factors. These regulate EMT effectors, which determine the epithelial, mesenchymal or metastable phenotype of the cell. Adapted from Lamouille et al. (2014). Abbreviations: BMP - bone morphogenic protein; BMPRs – bone morphogenic protein receptors; TGF-b - transforming growth factor beta; TGF-bRs transforming growth factor beta receptors; SHCA – SRC homology 2 domain-containing-transforming A GRB2 – growth factor receptor-bound protein 2; SOS – son of sevenless; EGF –
epidermal growth factor; HGF – hepatocyte growth factor; IGF – insulin-like growth factor; HES1 – hairy and enhancer of split 1; PTEN – phosphatase and TENsin homolog; FZD – Frizzled; GSK3β – glycogen synthase kinase-3β; Sonic hedgehog; SHH – PTCH – Patched; SMO – Smoothened; GLI – glioma-associated; ZEB – zinc-finger E-box-binding; MMPs – matrix metalloproteinases
Table I. Members of the human GALNT family, which add the first GalNAc monosaccharide in mucin type O-linked glycosylation, with alternative nomenclature and gene location

<table>
<thead>
<tr>
<th>GALNT</th>
<th>Has also been known as</th>
<th>Accession number</th>
<th>Chromosome locus</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>GALNT1</td>
<td></td>
<td>X85018</td>
<td>18q12.1</td>
<td>White et al., 1995</td>
</tr>
<tr>
<td>GALNT2</td>
<td></td>
<td>X85019</td>
<td>1q41-q42</td>
<td>White et al., 1995</td>
</tr>
<tr>
<td>GALNT3</td>
<td></td>
<td>X92689</td>
<td>2q24-q31</td>
<td>Bennett et al., 1996</td>
</tr>
<tr>
<td>GALNT4</td>
<td>POC1B</td>
<td>Y08564</td>
<td>12q21.33</td>
<td>Bennett et al., 1998</td>
</tr>
<tr>
<td>GALNT5</td>
<td>AJ245539</td>
<td>2q24.1</td>
<td></td>
<td>Ten Hagen et al., 1998</td>
</tr>
<tr>
<td>GALNT6</td>
<td></td>
<td>Y08565</td>
<td>12q13</td>
<td>Bennett et al., 1999a;</td>
</tr>
<tr>
<td>GALNT7</td>
<td>AJ002744</td>
<td>4q34.1</td>
<td></td>
<td>Bennett et al., 1999b</td>
</tr>
<tr>
<td>GALNT8</td>
<td>AJ271385</td>
<td>12p13.3</td>
<td></td>
<td>White et al., 2000</td>
</tr>
<tr>
<td>GALNT9</td>
<td>AB040672</td>
<td>12q24.33</td>
<td></td>
<td>Toba et al., 2000</td>
</tr>
<tr>
<td>GALNT10</td>
<td>AJ505950</td>
<td>5q33.2</td>
<td></td>
<td>Cheng et al., 2002</td>
</tr>
<tr>
<td>GALNT11</td>
<td>Y12434</td>
<td>7q36.1</td>
<td></td>
<td>Schwientek et al., 2002</td>
</tr>
<tr>
<td>GALNT12</td>
<td>AJ32365</td>
<td>9q22.33</td>
<td></td>
<td>Guo et al., 2002</td>
</tr>
<tr>
<td>GALNT13</td>
<td>AJ505991</td>
<td>2q24.1</td>
<td></td>
<td>Zhang et al., 2003</td>
</tr>
<tr>
<td>GALNT14</td>
<td>FLJ12691</td>
<td>Y09324</td>
<td>2q23.1</td>
<td>Wang et al., 2003</td>
</tr>
<tr>
<td>GALNT15</td>
<td>GALNTL2, PIH5</td>
<td>NM_054110</td>
<td>3q25.1</td>
<td>Cheng et al., 2004</td>
</tr>
</tbody>
</table>

(http://afmb.cnrs-mrs.fr/fr/CAZY/)
<table>
<thead>
<tr>
<th>GALNT16</th>
<th>GLANTL1, KIAA1130</th>
<th>AJ505951</th>
<th>14q24.1</th>
<th>Peng et al., 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>GALNT17</td>
<td>GALNTL6, GALNT20</td>
<td>AJ626725</td>
<td>4q34.1</td>
<td>Raman et al., 2012</td>
</tr>
<tr>
<td>GALNT18</td>
<td>GALNTL4, GALNT15, MGC71806</td>
<td>AJ626724</td>
<td>11p15.3</td>
<td>Raman et al., 2012</td>
</tr>
<tr>
<td>GALNT19</td>
<td>GALNTL3, GALNT16, GALNT20, WBSCR17</td>
<td>AJ626726</td>
<td>7q11.23</td>
<td>Nakamura et al., 2005</td>
</tr>
<tr>
<td>GALNT20</td>
<td>GALNTL5, GALNT15, WBSCR17</td>
<td>NM_145292</td>
<td>7p36.1</td>
<td>Raman et al., 2012</td>
</tr>
<tr>
<td>GALNT</td>
<td>Summary description of tissue distribution</td>
<td>Detailed description of tissue distribution</td>
<td>References</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>GALNT1</td>
<td>Ubiquitous</td>
<td>Homa et al., 1993; White et al., 1995; Toba et al., 2000; Zhang et al., 2003; Peng et al., 2010; Bennett et al., 2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GALNT2</td>
<td>Ubiquitous</td>
<td>Homa et al., 1993; White et al., 1995; Toba et al., 2000; Zhang et al., 2003; Peng et al., 2010; Bennett et al., 2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GALNT3</td>
<td>Widely</td>
<td>Highly expressed in pancreas and testis; weakly in kidney, prostate, ovary, intestine and colon; low levels in placenta, lung and spleen; also found in germ cells</td>
<td>Bennett et al., 1996; Bennett et al., 1999a Bennett et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT4</td>
<td>Widely</td>
<td>Highly expressed in sublingual salivary gland, stomach, colon, small intestine, lung, cervix, and uterus; lower levels in kidney, liver, heart, brain, spleen and ovary</td>
<td>Hagen et al., 1997; Bennett et al., 1998; Ten Hagen et al., 1998</td>
<td></td>
</tr>
<tr>
<td>GALNT5</td>
<td>Widely</td>
<td>Sublingual salivary gland; weak expression in stomach, small intestine and colon</td>
<td>Ten Hagen et al., 1998</td>
<td></td>
</tr>
<tr>
<td>GALNT6</td>
<td>Widely</td>
<td>Placenta and trachea; weakly in brain and pancreas</td>
<td>Bennett et al., 1999a</td>
<td></td>
</tr>
<tr>
<td>GALNT7</td>
<td>Widely</td>
<td>Pancreas, uterus, retina, kidney, small intestine, omentum, stomach and central nervous system</td>
<td>Bennett et al., 1999b Bennett et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT8</td>
<td>Limited</td>
<td>Testis and colon</td>
<td>White et al., 2000; Raman et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT9</td>
<td>Limited</td>
<td>Brain and spinal cord</td>
<td>Toba et al., 2000</td>
<td></td>
</tr>
<tr>
<td>GALNT10</td>
<td>Widely</td>
<td>Highly expressed in small intestine; less so in stomach, pancreas, ovary, thyroid gland and spleen</td>
<td>Cheng et al., 2002</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Expression</td>
<td>Expression Details</td>
<td>References</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>GALNT11</td>
<td>Widely</td>
<td>Highly expressed in kidney; weakly expressed in most other organs</td>
<td>Schwientek et al., 2002</td>
<td></td>
</tr>
<tr>
<td>GALNT12</td>
<td>Widely</td>
<td>Digestive organs; highly expressed in small intestine, stomach, pancreas, and colon. Expressed to a limited extent in the testis, thyroid gland and spleen</td>
<td>Guo et al., 2002</td>
<td></td>
</tr>
<tr>
<td>GALNT13</td>
<td>Limited</td>
<td>Neurons, adult cerebellum, cerebral cortex, and whole brain</td>
<td>Zhang et al., 2003</td>
<td></td>
</tr>
<tr>
<td>GALNT14</td>
<td>Wide</td>
<td></td>
<td>Bennett et al. 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT15</td>
<td>Wide</td>
<td>Highly expressed in small intestine, placenta, spleen, cerebral cortex, and ovary, less so in uterus, mammary gland, stomach, cerebellum, and whole brain</td>
<td>Cheng et al., 2004</td>
<td></td>
</tr>
<tr>
<td>GALNT16</td>
<td>Wide</td>
<td>Highly expressed in heart, brain and testis, and in germ cells</td>
<td>Identified as T20 by Peng et al., 2010 but actually T16 according to Bennett et al., 2012; Raman et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT17</td>
<td>Limited</td>
<td>Brain and testis</td>
<td>Peng et al., 2010; Raman et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT18</td>
<td>Limited</td>
<td>Highly expressed in testis, thyroid and adult brain</td>
<td>Raman et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT19</td>
<td>Limited</td>
<td>Cerebellum, cerebral cortex and heart</td>
<td>Nakamura et al., 2005; Raman et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT20</td>
<td>Limited</td>
<td>Testis</td>
<td>Raman et al, 2012</td>
<td></td>
</tr>
</tbody>
</table>
### Table III. Summary of major studies linking altered GALNT levels in cancers with prognosis, cancer cell behaviour, GalNAc O-glycosylation and EMT

<table>
<thead>
<tr>
<th>GALNT</th>
<th>Cancer type</th>
<th>Changes reported in Cancer</th>
<th>Associated altered GalNAc O-glycosylation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GALNT1</strong></td>
<td>Colorectal</td>
<td>Increased prevalence in cancer compared to normal determined by immunohistochemistry.</td>
<td>Not assessed</td>
<td>Kohsaki et al., 2000</td>
</tr>
<tr>
<td></td>
<td>Bladder</td>
<td>Increased expression in cancer compared to normal determined by DNA microarray; Knockdown inhibited cell proliferation and tumour growth in mice</td>
<td>Not assessed</td>
<td>Ding et al., 2012</td>
</tr>
<tr>
<td></td>
<td>Liver</td>
<td>Increased expression associated with poorer survival. Knockdown in hepatocellular carcinoma cells reduces cell migration and invasion due to reduced O-glycosylation of EGFR</td>
<td>Knockdown decreases O-glycosylation of EGFR, determined by VVA labelling after benzyl-α-GalNAc treatment</td>
<td>Huang et al., 2015</td>
</tr>
<tr>
<td><strong>GALNT2</strong></td>
<td>Colorectal</td>
<td>Increased prevalence in cancer compared to normal determined by immunohistochemistry.</td>
<td>Not assessed</td>
<td>Kohsaki et al., 2000</td>
</tr>
<tr>
<td></td>
<td>Hepatocellular</td>
<td>Downregulated in cancer compared to normal determined by immunohistochemistry and RT-PCR, associated with vascular invasion and recurrence. Over-expression in cancer cell lines suppresses invasion and migration and supresses tumour growth in mice</td>
<td>GALNT2 O-glycosylates EGFR with Tn antigen, determined by VVA pulldown and labelling on western blot</td>
<td>Wu et al., 2011</td>
</tr>
<tr>
<td></td>
<td>Oral squamous</td>
<td>Detectable at invasive edge of high grade clinical tumours, assessed by immunohistochemistry. Knockdown in oral squamous</td>
<td>GALNT2 O-glycosylates EGFR with Tn antigen, as determined by</td>
<td>Lin et al., 2014</td>
</tr>
<tr>
<td>Tissue Type</td>
<td>Description</td>
<td>Methodology</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Immunopositivity associated with early stage and favourable prognosis, and over-expression resulted in smaller tumours in mice. Overexpression reduced cell migration and invasion by increased O-glycosylation of IGF-1R preventing its dimerization</td>
<td>Overexpression increased Tn antigen on IGF-1R, determined by VVA pull down</td>
<td>Ho et al., 2014</td>
<td></td>
</tr>
<tr>
<td>Gastric</td>
<td>Reduced levels, determined by immunohistochemistry, associated with advanced disease and shorter recurrence free survival. Knockdown in gastric adenocarcinoma cells increased cell migration and invasion by reducing O-glycosylation and enhancing phosphorylation of HGFR, and promoted metastasis in a mouse model</td>
<td>Knockdown reduced VVA binding to HGFR in western blot</td>
<td>Liu et al., 2016</td>
<td></td>
</tr>
<tr>
<td>Glioma</td>
<td>Immunopositivity associated with high grade and poor prognosis. Knockdown in glioma cells reduced cell migration and invasion, and less aggressive tumours in a mouse model, by reduced O-glycosylation of EGFR</td>
<td>GALNT2 O-glycosylates EGFR with Tn antigen, as determined by VVA binding on western blot</td>
<td>Sun et al., 2019</td>
<td></td>
</tr>
<tr>
<td>Lung adenocarcinoma</td>
<td>High levels correlate with poor prognosis determined by immunohistochemistry and in patient datasets. Overexpression activates the Notch/Hes1-PTEN-PI3K/Akt signalling pathway</td>
<td>Not assessed</td>
<td>Wang et al., 2021</td>
<td></td>
</tr>
<tr>
<td>GALNT3</td>
<td>Colorectal</td>
<td>Strong presence in patient samples as determined by</td>
<td>Not assessed</td>
<td>Shibao et al., 2002</td>
</tr>
<tr>
<td>Tissue</td>
<td>Description</td>
<td>Study</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>Lung non small cell</td>
<td>Low levels, assessed by immunohistochemistry, associated with loss of differentiation, high rates of cell division and poor survival</td>
<td>Not assessed</td>
<td>Dosaka-Akita et al., 2002</td>
<td></td>
</tr>
<tr>
<td>Gastric</td>
<td>Weak presence in patient samples determined by immunohistochemistry is an independent prognostic marker of improved 5 year survival</td>
<td>Not assessed</td>
<td>Onitsuka et al., 2003</td>
<td></td>
</tr>
<tr>
<td>Gallbladder</td>
<td>Increased expression in cancer compared to normal as determined by qPCR. Presence of diffuse type localisation in subserosal layer determined by immunohistochemistry associated with poor prognosis</td>
<td>Not assessed</td>
<td>Miyahara et al., 2004</td>
<td></td>
</tr>
<tr>
<td>Lung adenocarcinoma</td>
<td>Low level determined by immunohistochemistry is a significant independent marker of poor prognosis</td>
<td>Not assessed</td>
<td>Gu et al., 2004</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>Increased presence in malignant compared to benign hyperplasia determined by qPCR and immunohistochemistry.</td>
<td>Not assessed</td>
<td>Landers et al., 2005</td>
<td></td>
</tr>
<tr>
<td>Oesophageal squamous</td>
<td>Increased presence in cancer compared to dysplasia and normal determined by immunohistochemistry. Associated with lymph node metastasis.</td>
<td>Not assessed</td>
<td>Ishikawa et al., 2005</td>
<td></td>
</tr>
<tr>
<td>Pancreatic</td>
<td>High presence in pancreatic cancer patient samples determined by immunohistochemistry. Over expressed in pancreatic cancer cell lines compared to normal</td>
<td>Not assessed</td>
<td>Taniuchi et al., 2011</td>
<td></td>
</tr>
<tr>
<td>Tissue Type</td>
<td>Expression Details</td>
<td>Not Assessed</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Immunopositivity associated with large tumour size, vascular invasion and poor survival; correlation with β-catenin immunopositivity but not with E-cadherin positivity.</td>
<td>Not assessed</td>
<td>Kitada et al., 2013</td>
<td></td>
</tr>
<tr>
<td>Ovarian epithelial</td>
<td>High levels in cancer compared to normal tissues, determined by immunohistochemistry, correlated with shorter progression free survival. Knockdown in epithelial ovarian cancer cells resulted in proteolysis of MUC1 through reduced O-glycosylation, and reduced proliferation, invasion and migration.</td>
<td>Not assessed</td>
<td>Wang et al., 2014</td>
<td></td>
</tr>
<tr>
<td>Oral squamous</td>
<td>Immunopositivity associated with poor differentiation, lymphatic and vascular invasion and recurrence.</td>
<td>Not assessed</td>
<td>Harada et al., 2016</td>
<td></td>
</tr>
<tr>
<td><strong>GALNT4</strong></td>
<td>Associated with enhanced recurrence free survival in patient datasets. Knockdown in breast cancer cell lines increased cell proliferation through activation of Notch signalling pathway.</td>
<td>Glycosylation by Tn antigen, assessed by VVA lectin blotting, decreased in multiple proteins after knockdown</td>
<td>Wu et al., 2021a</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>Upregulated in luminal type cancers, and associated with improved recurrence free survival in patient datasets. Knockdown in breast cancer cell lines decreased O-glycosylation of TGFβ type I and type II receptors which led to increased dimerization and activity.</td>
<td>Tn antigen presence on TGFβ type I and type II receptors reduced after knockdown, as assessed by VVA pulldown. Ser31 on the extracellular domain of TGFβ type II receptor identified as being the O-</td>
<td>Wu et al., 2021b</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Tissue</td>
<td>Findings</td>
<td>Methodology</td>
<td>Reference</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>GALNT4</td>
<td>Gastric</td>
<td>Reduced levels, determined by immunohistochemistry, is an independent predictor of poor prognosis.</td>
<td>Not assessed</td>
<td>He et al., 2014</td>
</tr>
<tr>
<td></td>
<td>Pancreatic</td>
<td>Reduced levels, determined by immunohistochemistry, in cancer compared to normal, and inversely correlated with MUC1 immunopositivity. Downregulated by MUC1 in cancer cells through binding to regulatory elements.</td>
<td>Not assessed</td>
<td>Caffrey et al., 2019</td>
</tr>
<tr>
<td>GALNT5</td>
<td>Breast</td>
<td>Immunopositivity rarely seen in normal but frequently in cancers, and significantly associated with stage 1 disease.</td>
<td>Not assessed</td>
<td>Berois et al., 2006a</td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>Increased expression in bone marrow samples from cancer patients and cell lines as determined using RT-PCR; significantly associated with subsequent recurrence in lymph node negative cases.</td>
<td>Not assessed</td>
<td>Freire et al., 2006</td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>Significantly higher presence in cancer samples compared to normal, determined by immunohistochemistry.</td>
<td>Not assessed</td>
<td>Patani et al., 2008</td>
</tr>
<tr>
<td></td>
<td>Gastric</td>
<td>Detected in normal, metaplastic and cancer samples using immunohistochemistry. In cancer, associated with vascular invasion.</td>
<td>Not assessed</td>
<td>Gomes et al., 2009</td>
</tr>
<tr>
<td></td>
<td>Breast</td>
<td>Immunohistochemistry reveals strong presence in cancer but not normal tissues. Knockdown in breast cancer cells reduces MUC1 stability</td>
<td>VVA pull down and western blot confirm GalNAc O-glycosylation of MUC1</td>
<td>Park et al., 2010</td>
</tr>
</tbody>
</table>
due to decreased O-glycosylation.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Description</th>
<th>Control/Assay</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatic</td>
<td>Independent prognostic indicator for pancreatic cancer, determined by immunohistochemistry; associated with good or moderate degree of differentiation, absence of vascular invasion and early stage; immunopositivity predicts improved survival.</td>
<td>Not assessed</td>
<td>Li et al., 2011</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>Highly expressed in clinical samples, assessed by analysis of publicly available datasets. Knockdown in pancreatic cancer cells causes decrease in P-cadherin and increase in E-cadherin and β-catenin and changes in morphology and cytoskeleton, also reduced invasiveness in transwell assay. Knockdown reduces expression of MUC4 and EGFR presumably through reduced O-glycosylation.</td>
<td>In vitro O-glycosylation assay confirms GALNT6 glycosylates MUC4 peptide, assessed by MALDI-TOF mass spectrometry, and identifies the 10th Thr within a peptide fragment as being the predominant O-glycosylation target of GALNT6</td>
<td>Tarhan et al., 2016</td>
</tr>
<tr>
<td>Ovarian epithelial</td>
<td>Elevated levels of GALNT6 correlate with lymph node and distant metastasis and reduced survival, determined by immunohistochemistry. Knockdown in epithelial ovarian cancer cells reduces cell migration and invasion by decreased O-glycosylation of EGFR.</td>
<td>VVA pull down confirmed that GALNT6 glycosylated EGFR with Tn antigen</td>
<td>Lin et al., 2017</td>
</tr>
<tr>
<td>Colorectal</td>
<td>Presence, determined by immunohistochemistry, in cancer samples predicts significantly better survival; undetectable in normal mucosa.</td>
<td>Not assessed</td>
<td>Ubillos et al., 2018</td>
</tr>
<tr>
<td>Colon</td>
<td>Strong presence in patient colon adenocarcinoma</td>
<td>Not assessed</td>
<td>Lavrsen et al., 2018</td>
</tr>
<tr>
<td>Tissue</td>
<td>Description</td>
<td>Methodology</td>
<td>Reference</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Breast</td>
<td>Poor breast cancer patient survival associated with increased expression, determined by analysis of publicly available datasets and immunohistochemistry. Knockdown in breast cancer cell lines inhibits PI3K/Akt signalling, presumably through reduced O-glycosylation of signalling pathway activator α2M, and reduces invasion in a transwell assay.</td>
<td>VVA pull down and western blot confirm GalNAc O-glycosylation of breast cancer cells by GALNT6</td>
<td>Liu et al., 2020</td>
</tr>
<tr>
<td>Lung adenocarcinoma</td>
<td>Immunopositivity associated with metastasis and poor prognosis in clinical samples. Over expression enhanced migration and invasion in a wound healing and matrigel assay and silencing inhibited metastasis in a mouse xenograft model. Knockdown increased expression of E-cadherin and reduced expression of N-cadherin and Slug. Overexpression of GRP78 caused relocation to ER thereby increasing O-glycosylation of ERK1/2.</td>
<td>VVA-lectin Western blot analysis showed enhanced O-glycosylation of GRP78</td>
<td>Song et al., 2020</td>
</tr>
<tr>
<td>Cervical</td>
<td>Upregulated in cervical cancer patient samples as determined by qPCR. Repression by miR-214 reduces cell proliferation, migration, and invasiveness.</td>
<td>Not assessed</td>
<td>Peng et al., 2012</td>
</tr>
<tr>
<td>Cervical</td>
<td>Overexpression, assessed by RT-qPCR, identified in clinical samples and cell lines; promotes cell proliferation and invasion by activating the EGFR/PI3K/Akt pathway in cervical cancer cells through O-glycosylation of EGFR.</td>
<td>Not assessed</td>
<td>Cao et al., 2020</td>
</tr>
</tbody>
</table>
**GALNT8**

Colorectal

Up-regulated in cancer tissues in comparison with normal, determined by RNASeq and immunohistochemistry, and co-expressed with GAU1. Expression associated with poor prognosis. Over-expression in cell lines enhanced colony formation and proliferation.

**Breast**

mRNA and immunohistochemistry reveal downregulation is associated with poor clinical outcome and lower ERα expression. Overexpression in cell lines reduces proliferation. Downregulation is associated with reduction in Erα through inhibition of the BMP/Smad/RUNX2 axis in breast cancer cell lines.

**GALNT9**

Neuroblastoma

Expression determined by RT-PCR significantly associated with high overall survival

**GALNT10**

Gastric

Greater immunopositivity in cancer than adjacent normal tissue; immunopositivity associated with higher grade.

**Gastric**

High levels in clinical samples, as determined by qRT-PCR, associated with lymph node and distant metastases and poor prognosis. Knockdown in cancer cells reduces proliferation and migration in a transwell assay, and also HOXD13 levels.

**GALNT11**

Chronic lymphocytic leukaemia

Overexpressed in B-cells of chronic lymphocytic leukaemia patients as determined by qPCR.

Not assessed

Tang et al., 2021

VVA and peanut lectin labelling confirm increased GALNT8 associated with O-GalNAcylation of total proteins and of BMPR1A

Huang et al., 2022

Expression associated with poor prognosis. Over-expression in cell lines enhanced colony formation and proliferation.

VVA and peanut lectin labelling confirm increased GALNT8 associated with O-GalNAcylation of total proteins and of BMPR1A

Huang et al., 2022

Expression determined by RT-PCR significantly associated with high overall survival

Not assessed

Berois et al., 2013

Not assessed

Gao et al., 2013

Not assessed

Xu et al., 2020b

Flow cytometry using VVA and monoclonal antibodies against Tn and T antigen demonstrated a low density of Tn antigen

Libisch et al., 2014
<table>
<thead>
<tr>
<th>GALNT12</th>
<th>Colorectal</th>
<th>Down regulated in colorectal cancer cell lines and tissues compared to normal as determined by RT-PCR, lower in cases with metastases.</th>
<th>Not assessed</th>
<th>Guo et al., 2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon</td>
<td>Inactivating somatic and germline mutations found in cancer samples.</td>
<td>Not assessed</td>
<td>Guda et al., 2009</td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td>Two deleterious variants identified that are highly likely to predispose to hereditary colorectal cancer.</td>
<td>Not assessed</td>
<td>Clarke et al., 2012</td>
<td></td>
</tr>
<tr>
<td>GALNT13</td>
<td>Neuroblastoma</td>
<td>Detected by QRT-PCR in bone marrow samples from stage 4 patients but not controls and highly correlated with poor outcome</td>
<td>Not assessed</td>
<td>Berois et al., 2006b</td>
</tr>
<tr>
<td>GALNT14</td>
<td>Breast</td>
<td>Presence increased in cancer compared to normal, determined by immunohistochemistry, and is associated with low histological grade</td>
<td>Not assessed</td>
<td>Wu et al., 2010</td>
</tr>
<tr>
<td>Ovarian</td>
<td>Upregulated in cancers, as determined by western blot and immunohistochemistry, and correlates with stage. Suppression in ovarian cancer cells causes a reduction in invasion and in MMP2 and -9 activity.</td>
<td>Not assessed</td>
<td>Yang et al., 2016</td>
<td></td>
</tr>
<tr>
<td>Ovarian</td>
<td>Overexpressed in cisplatin resistant cancers, determined by analysis of publicly available datasets and western blot. Downregulation significantly decreases O-glycosylation of EGFR leading to inhibition of the EGFR/PI3K/Akt signalling pathway</td>
<td>EGFR glycosylated with Tn antigen, determined by VVA pulldown</td>
<td>Li et al., 2021</td>
<td></td>
</tr>
<tr>
<td>GALNT15</td>
<td>Colorectal</td>
<td>SNPs analysis of cases versus controls identified GALNT15 as</td>
<td>Not assessed</td>
<td>Abulí et al., 2011</td>
</tr>
</tbody>
</table>


predicting increased cancer risk

GALNT16 to GALNT20 Not reported
Figure 1. Phylogenetic tree depicting the evolutionary divergence of the GALNT family from the hypothesised ancestral GALNT gene. GALNTs with * are termed sub-family Y and have been proposed to act as chaperones for the other GALNT family members. Adapted from Bennett et al. (2012).
Figure 2. Schematic representation of the shared type II membrane structure of the GALNTs. The luminal portion consists of a catalytic domain, a ricin-like lectin domain and a variable length stem region. They are held in place by a hydrophobic transmembrane domain followed by a short N-terminal tail. Adapted from Beaman and Brooks (2014).
Figure 3. The sequence of events in metastasis. (1) Angiogenesis, the development of tumoural blood supply. (2) Dissemination of cancer cells from the primary tumour mass by invasion of local basement membrane and migration through stroma. (3) Intravasation of cancer cell into a blood (or lymphatic) vessel followed by (4) hematogenous (or lymphatic) dissemination, where, in the case of hematogenous dissemination, the cancer cells can form rafts with platelets and white blood cells. (5) Adhesion to the vascular endothelium. (6) Extravasation out of the blood (or lymphatic) vessel. (7) Invasion through stroma. (8) Formation a secondary tumour, where (1) angiogenesis is induced again. Cancer cell plasticity through EMT/MET is a feature of multiple stages during metastasis. In the primary tumour, cancer cells will be epithelial-like; to be able to detach from the primary tumour mass, the cell transdifferentiates to mesenchymal-like. The mesenchymal-like cancer cell can invade through basement membrane, surrounding stroma and then intravasate into a blood (or lymphatic) vessel. During haematogenous (or lymphatic) dissemination, the cancer cell transdifferentiates into epithelial-like and can adhere to the endothelium and initiate extravasation. The epithelial-like cancer cell transdifferentiates into mesenchymal-like allowing it to invade the local stroma and migrate to a secondary site. At the secondary site, the mesenchymal-like cancer cell transdifferentiates into epithelial-like and can give rise to a secondary tumour.
**Figure 4.** During epithelial mesenchymal transition (EMT), epithelial cells down-regulate cell-cell adhesion structures. Loss of adherins junctions and tight junctions alter the cell polarity from apico-basal to anterior-posterior, changing the cell morphology from cuboidal to spindle-shaped, and allowing apical and basolateral membrane components to merge. The actin cytoskeleton is transformed into stress fibres which accumulate at cell protrusions. Epithelial intermediate filaments, the cytokeratins, are replaced by vimentin. The basement membrane is dissolved allowing motile mesenchymal cells to invade the surrounding stroma. Cells become resistant to anoikis. Epithelial-specific markers including E-cadherin are replaced by mesenchymal N-cadherin and αvβ6 integrin. The process is reversible, with motile mesenchymal cells reverting to stationary, adhesive epithelial cells, termed mesenchymal epithelial transition (MET).
Figure 5. Transcriptional regulation of tumour associated epithelial mesenchymal transition (EMT): EMT is induced by autocrine/paracrine secretion of growth factors, cytokines and extracellular matrix proteins, which are secreted in response to hypoxia and inflammation. Binding of these EMT inducing signals to their specific receptors on the cell surface triggers a myriad of intracellular signalling networks which can act pleiotropically to induce EMT transcription factors. These regulate EMT effectors, which determine the epithelial, mesenchymal or metastable phenotype of the cell. Adapted from Lamouille et al. (2014).

Abbreviations: BMP - bone morphogenic protein; BMPRs – bone morphogenic protein receptors; TGF-b - transforming growth factor beta; TGF-bRs transforming growth factor beta receptors; SHCA – SRC homology 2 domain-containing-transforming A GRB2 – growth factor receptor-bound protein 2; SOS – son of sevenless; EGF-epidermal growth factor; HGF – hepatocyte growth factor; IGF – insulin-like growth factor; HES1 – hairy and enhancer of split 1; PTEN – phosphatase and TENsin homolog; FZD – Frizzled; GSK3b - glycogen synthase kinase-3β ; Sonic hedgehog;SHH – PTCH – Patched; SMO – Smoothened; GLI – glioma-associated; ZEB – zinc-finger E-box-binding; MMPs – matrix metalloproteinases.